Close Menu

Guava Technologies announced unexpectedly last week that Rajen Dalal, the company’s president and CEO for the last three years, has resigned.

Taking over for Dalal on an interim basis is John Walker, the chairman of Guava’s board of directors.

Last week, Dalal told Inside Bioassays that his decision to resign was primarily due to a disagreement about which markets Guava should commit the bulk of its money to over the coming year: drug-discovery tools or clinical diagnostics.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.